Multivariable Cox regression clinical stage IV NSCLC (subtypes of systemic therapy); (aHR (95% CI)) for mortality associated with time-to-treatment
| Time-to-treatment quartiles (days) | Stage IV chemotherapy and/or immunotherapy (N=3715) | Stage IV targeted therapy (N=1553) | ||
| aHR* (95% CI) | P value | aHR† (95% CI) | P value | |
| 1 (0–21 days) | Ref | - | Ref | - |
| 2 (22–35 days) | 0.87 (0.79 to 0.97) | 0.0081 | 0.97 (0.81 to 1.16) | 0.711 |
| 3 (36–49 days) | 0.80 (0.72 to 0.89) | <0.0001 | 0.95 (0.78 to 1.15) | 0.59 |
| 4 (>49 days) | 0.72 (0.64 to 0.81) | <0.0001 | 0.96 (0.79 to 1.17) | 0.7004 |
*Time-to-treatment adjusted for gender, age, socioeconomic status, performance status, histology, distant metastasis (cM1a vs cM1b/cM1c).
†Time-to-treatment adjusted for gender, age, performance status, histology, distant metastasis (cM1a vs cM1b/cM1c).
aHR, adjusted HR; NSCLC, non-small cell lung cancer.